Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: Differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs

Journal of Nuclear Medicine

Volumn 41, Issue 3, 2000, Pages 531-537

  Kotzerke, Jörg ^a   Glatting, Gerhard ^b   Seitz, Ulrike ^b   Rentschier, Marion ^b   Neumaier, Bernd ^b   Bunjes, Donald ^b   Duncker, Christian ^b   Dohr, Dagmar ^b   Bergmann, Lothar ^b   Reske, Sven N ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b NONE

Author keywords

188Re; Bone marrow transplantation; Dosimetry; Monoclonal antibody against nonspecific cross reacting antigen 95; Radioimmunotherapy

Indexed keywords

CROSS REACTING ANTIGEN; MONOCLONAL ANTIBODY NCA 95; MONOCLONAL ANTIBODY NCA 95 RHE 188; MONOCLONAL ANTIBODY NCA 95 TC 99M; POTASSIUM PERCHLORATE; RHENIUM 188; SODIUM PERCHLORATE; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; BETA RADIATION; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; DOSIMETRY; DRUG DISTRIBUTION; FEMALE; HUMAN; IMMUNOMODULATION; ISOTOPE LABELING; LEUKEMIA; MALE; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIOIMMUNOTHERAPY; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PHANTOMS, IMAGING; RADIOIMMUNOTHERAPY; RADIOMETRY; RHENIUM; TECHNETIUM; TISSUE DISTRIBUTION; TRANSPLANTATION CONDITIONING;

EID: 0034050410     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 1995;85:1122-1131.
2. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood. 1990;76:1867-1871.
3. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood. 1991;77:1660-1665.
4. Scheinberg DA, Lovett D, Divgi CR, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol. 1991;9:478-490.
5. Appelbaum FR, Matthews DC, Eary JF, et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation. 1992;54:829-833.
6. Matthews DC, Badger CC, Fisher DR, et al. Selective radiation of hematolymphoid tissue delivered by anti-CD45 antibody. Cancer Res. 1992;52:1228-1234.
7. Schwartz MA, Lovett DR, Redner A, et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol. 1993;11:294-303.
8. Knapp FF Jr, Beets AL, Guhlke S, et al. Availability of rhenium-188 from the alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment. Anticancer Res. 1997;17: 1783-1795.
9. Breitz HB, Fisher DR, Weiden PL, et al. Dosimetry of rhenium-186-labeled monoclonal antibodies: methods, prediction from technetium-99m-labeled antibodies and results of phase I trials. J Nucl Med. 1993;34:908-917.
10. Griffiths GL, Goldenberg DM, Diril H, Hansen HJ. Technetium-99m, rhenium-186, and rhenium-188 direct-labeled antibodies. Cancer. 1994;73:761-768.
11. Juweid M, Sharkey RM, Swayne LC, Griffiths GL, Dunn R, Goldenberg DM. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer. J Nucl Med. 1998;39:34-42.
12. Seitz U, Neumaier B, Glatting G, Seitz U, Neumaier B, Glatting G. Preparation and evaluation of the rhenium-188-labeled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia. Eur J Nucl Med. 1999;26:1265-1273.
13. Becker W, Goldenberg DM, Wolf F. The use of monoclonal antibodies and antibody fragments in the imaging of infectious lesions. Semin Nucl Med. 1994;24:142-153.
14. Reske SN, Karstens JH, Gloeckner W, et al. Radioimmunoimaging for diagnosis of bone marrow involvement in breast cancer and malignant lymphoma. Lancet. 1989;1:299-301.
15. Reske SN. Recent advances in bone marrow scanning. Eur J Nucl Med. 1991;18:203-221.
16. Reske SN, Karstens JH, Henrich MM, et al. Detection of bone involvement in malignant diseases by immunoscintigraphy of the bone marrow. Nuklearmedizin. 1993;32:111-119.
17. Guhlmann A, Brecht Krauss D, Suger G, et al. Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings. Radiology. 1998;206:749-754.
18. Guhlmann A, Brecht Krauss D, Suger G, et al. Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis. J Nucl Med. 1998;39:2145-2152.
19. Knapp FF Jr, Mirzadeh S. The continuing important role of radionuclide generator systems for nuclear medicine. Eur J Nucl Med. 1994;21:1151-1165.
20. Kotzerke J, Rentschler M, Glatting G, et al. Dosimetric fundamentals of endovascular brachytherapy using Re-188 to prevent restenosis after angioplasty. Nuklearmedizin. 1998;37:68-72.
21. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
22. Dey HM, Seibyl JP, Stubbs JB, et al. Human biodistribution and dosimetry of the SPECT benzodiazepine receptor radioligand iodine-123-iomazenil. J Nucl Med. 1994;35:399-404.
23. 123I-iodo-alpha-methyltyrosine. Eur J Nucl Med. 1997;24:1162-1166.
24. Kotzerke J, Fenchel S, Guhlmann A, et al. Pharmacokinetics of Tc-99m-pertechnetate and Re-188-perrhenate after oral administration of perchlorate: option for subsequent care after the use of liquid Re-188 in a balloon catheter. Nucl Med Commun. 1998;19:795-801.
25. Deutsch E, Libson K, Vanderheyden JL, Ketring AR, Maxon HR. The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. Int J Rad Appl Instrum B. 1986;13: 465-477.
26. Cristy M. Active bone marrow distribution as a function of age in humans. Phys Med Biol. 1981;26:389-400.
27. Chung JK, Yeo J, Lee DS, et al. Bone marrow scintigraphy using technetium-99m-antigranulocyte antibody in hematologic disorders. J Nucl Med. 1996;37:978-982.
28. Huic D, Ivancevic V, Richter WS, Munz DL. Immunoscintigraphy of the bone marrow: normal uptake values of technetium-99m-labeled monoclonal antigranulocyte antibodies. J Nucl Med. 1997;38:1755-1758.
29. Badger CC, Fisher DR. The importance of accurate radiation dosimetry in radioimmunotherapy of cancer. J Nucl Med. 1994;35:300-302.
30. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol. 1998;16:3246-3256.
31. Berberich R, Hennes P, Alexander C. The detection of inflammation and the formation of HAMA following the administration of monoclonal antibody BW 250/183. Nuklearmedizin. 1992;31:70-73.
32. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol. 1998;16:3270-3278.
33. Siegel JA. Revised Nuclear Regulatory Commission regulations for release of patients administered radioactive materials: outpatient iodine-131 anti-B1 therapy. J Nucl Med. 1998;39(suppl):28S-33S.